Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 86,205,648
  • Shares Outstanding, K 1,634,540
  • Annual Sales, $ 20,776 M
  • Annual Income, $ 1,007 M
  • 36-Month Beta 0.99
  • Price/Sales 4.15
  • Price/Cash Flow 14.99
  • Price/Book 6.68

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.96 +5.50%
on 05/08/18
53.40 -1.29%
on 05/17/18
+0.41 (+0.78%)
since 04/18/18
3-Month
49.96 +5.50%
on 05/08/18
68.88 -23.48%
on 02/27/18
-16.25 (-23.56%)
since 02/16/18
52-Week
49.96 +5.50%
on 05/08/18
70.05 -24.75%
on 02/16/18
-1.07 (-1.99%)
since 05/18/17

Most Recent Stories

More News
Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer

European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.

EXEL : 21.58 (+0.09%)
RHHBY : 27.9300 (-0.07%)
PFE : 35.64 (-0.20%)
BMY : 52.71 (-0.06%)
Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology-Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018

--Updated data from Phase 3 CheckMate -238 study of Opdivo as adjuvant treatment in Stage III/IV melanoma will further explore potential durability of recurrence-free survival

BMY : 52.71 (-0.06%)
Illumina Takes Over Edico Genome, Fortifies NGS Platform

Illumina (ILMN) proceeds with deals to boost NGS platform.

COO : 233.31 (+1.08%)
ILMN : 269.67 (+0.45%)
ISRG : 458.79 (+0.19%)
BMY : 52.71 (-0.06%)
Dutch Company Xenikos Secures USD 30 Million in Series B Financing

AMGN : 176.30 (+0.94%)
CELGZ : 0.25 (-3.85%)
BMY : 52.71 (-0.06%)
NERV : 7.95 (+7.43%)
Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the UBS 2018 Global Healthcare Conference on Tuesday, May 22, 2018, in New York. Charles Bancroft, executive vice president,...

BMY : 52.71 (-0.06%)
Nektar (NKTR) Q1 Loss Wider Than Expected, Sales Soar Y/Y

Nektar (NKTR) reports wider-than-expected loss in Q1 while revenues rise substantially year over year. It collaborates with Bristol-Myers for advancing immuno-oncology and immunology pipeline.

LLY : 82.07 (+0.50%)
SHPG : 169.61 (-1.19%)
BMY : 52.71 (-0.06%)
NKTR : 85.30 (+7.66%)
Eliquis (Apixaban; Bristol-Myers Squibb/Pfizer) Drug Overview 2017/18-2026: An Orally Available Factor Xa Inhibitor Indicated for the Prevention of Venous Thromboembolsim - ResearchAndMarkets.com

The "Drug Overview: Eliquis" report has been added to ResearchAndMarkets.com's offering.

BMY : 52.71 (-0.06%)
Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down

Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.

CLDX : 0.67 (-2.90%)
ENTA : 104.41 (-1.61%)
LLY : 82.07 (+0.50%)
BMY : 52.71 (-0.06%)
Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates

Lilly signs deal to buy immuno-oncology biotech ARMO Biosciences for about $1.6 billion. J&J's Darzalex gains FDA approval in first-line setting.

AZN : 36.33 (-0.30%)
JNJ : 124.24 (+0.31%)
LLY : 82.07 (+0.50%)
RHHBY : 27.9300 (-0.07%)
ARMO : 49.87 (+0.14%)
GSK : 40.03 (-0.17%)
BMY : 52.71 (-0.06%)
Horizon Pharma (HZNP) Q1 Earnings & Sales Miss, Shares Fall

Horizon Pharma (HZNP) misses earnings and sales estimates in Q1. However, the orphan unit and the rheumatology business continue to grow.

HZNP : 15.11 (+0.27%)
MRK : 59.14 (+0.12%)
RHHBY : 27.9300 (-0.07%)
BMY : 52.71 (-0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 53.48
1st Resistance Point 53.10
Last Price 52.71
1st Support Level 52.38
2nd Support Level 52.04

See More

52-Week High 70.05
Fibonacci 61.8% 62.38
Fibonacci 50% 60.01
Fibonacci 38.2% 57.63
Last Price 52.71
52-Week Low 49.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar